ClinicalTrials.gg
CompletedNCT01034111Updated May 30, 2017Results posted

A Local Experiential Study With Sitagliptin (an Antihyperglycemic Drug) in 30 Patients With Type 2 Diabetes Mellitus (0431-178)

A Phase 3 interventional study of Sitagliptin phosphate and Metformin in Type 2 Diabetes, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2017-05-30.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
149th of 197
30 · median 102
Started
2010
with 22 others
Phase 3
74 of 198
none open now
Registered
78th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 149th largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2010, is one of 74 in phase 3, and was the 78th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will assess, over a 4-week treatment period, the safety and efficacy of the addition of sitagliptin to metformin in participants with type 2 diabetes mellitus (T2DM) who failed to achieve glycemic control on metformin monotherapy.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with T2DM failing metformin monotherapy
  • Between the ages of 18 and 79

Exclusion criteria

Exclusion Criteria:

  • Participants has a history of type 1 Diabetes Mellitus or ketoacidosis
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Sitagliptin

    Sitagliptin as add-on therapy to a stable dose of metformin

    Drug: Sitagliptin phosphate · Drug: Metformin

Interventions

  • Sitagliptin 100 mg tablet by mouth once daily for 4 weeks.

    Also known as: MK-0431, Januvia

  • Stable dose of metformin tablet(s) by mouth (at least 1000 mg/day) for 4 weeks.

    Also known as: Glucophage

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of Sitagliptin After 4 Weeks of Treatment

    Safety \& tolerability were measured in terms of the # of participants with \>=1 adverse event (AE), \>=1 drug-related AE, \>=1 serious AE (SAE), or discontinued treatment due to an AE. SAEs included events occurring after initiation of glycemic rescue therapy. AE is defined as any unfavorable/unintended change in structure, function, or chemistry of the body temporally associated with the use of SPONSOR's product. SAE is defined as any AE that results in death, is life-threatening, an overdose, causes or prolongs in-patient hospitalization, or considered medically significant by the investigator.

    Time frame: 4 weeks

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose at Week 4

    Calculated as the mean change from baseline in fasting plasma glucose at Week 4.

    Time frame: Baseline and Week 4

07

Results

Posted Nov 6, 2011

Participant flow

Participant flow — Overall Study
MilestoneSitagliptin
Started30
Completed30
Not completed0

Outcome measures

PrimarySafety and Tolerability of Sitagliptin After 4 Weeks of Treatment

Safety \& tolerability were measured in terms of the # of participants with \>=1 adverse event (AE), \>=1 drug-related AE, \>=1 serious AE (SAE), or discontinued treatment due to an AE. SAEs included events occurring after initiation of glycemic rescue therapy. AE is defined as any unfavorable/unintended change in structure, function, or chemistry of the body temporally associated with the use of SPONSOR's product. SAE is defined as any AE that results in death, is life-threatening, an overdose, causes or prolongs in-patient hospitalization, or considered medically significant by the investigator.

Time frame:
4 weeks
Reported as:
Number · Participants
Safety and Tolerability of Sitagliptin After 4 Weeks of Treatment
ParticipantsSitagliptin
At least one adverse event5
At least one drug-related adverse event5
At least one serious adverse event0
Discontinued treatment due to an adverse event0
SecondaryChange From Baseline in Fasting Plasma Glucose at Week 4

Calculated as the mean change from baseline in fasting plasma glucose at Week 4.

Time frame:
Baseline and Week 4
Reported as:
Mean · mmol/L
Change From Baseline in Fasting Plasma Glucose at Week 4
mmol/LSitagliptin
Change From Baseline in Fasting Plasma Glucose at Week 41.6 ± 2.2

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin—0/30 (0%)4/30 (13.3%)
Most frequent other events
Most frequent other events
EventSitagliptin
Hepatic Enzyme IncreasedInvestigations2/30
Decreased AppetiteMetabolism and nutrition disorders2/30

Baseline characteristics

Age, Customized
Age, Customized(Participants)Sitagliptin
<= 40 years5
41 to 50 years8
51 to 60 years7
>= 60 years10
Sex: Female, Male
Sex: Female, Male(Participants)Sitagliptin
Female20
Male10
Baseline Fasting Plasma Glucose
Baseline Fasting Plasma Glucose(mmol/L)Sitagliptin
Mean8.9 ± 1.5
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2010 to primary completion in Oct 2010, 7 months.

Results were first posted in Nov 2011, 1 year 1 month after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 7 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2009
First posted
Dec 17, 2009
StartActual
Mar 1, 2010
Primary completionActual
Oct 4, 2010
CompletionActual
Oct 4, 2010
Results first posted
Nov 6, 2011
Last update
May 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01034111
Responsible party
Sponsor
First posted
Dec 17, 2009
Start date
Mar 1, 2010
Primary completion
Oct 4, 2010
Completion
Oct 4, 2010
Results posted
Nov 6, 2011
Last update
May 30, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sitagliptin · Metformin

Start the discussion